Also known as: Vascular Bioregulator, KED, Lys-Glu-Asp tripeptide
Half-life: Short (minutes); biological effect persists via gene-expression modulation
Last reviewed: · Published:
Vesugen is a short peptide bioregulator from the Khavinson family, reported as the tripeptide Lys-Glu-Asp (KED), designed for vascular and endothelial applications. It is proposed to target vascular endothelial gene expression to support normal endothelial function, modulate age-related arterial stiffness, and potentially address aspects of atherosclerosis progression. The compound has been used in Russian clinical settings for hypertension adjunct therapy, age-related vascular decline, and post-stroke vascular recovery.
Russian clinical-observational studies have evaluated Vesugen in elderly patients with cardiovascular risk factors, with reported improvements in flow-mediated dilation, arterial stiffness measures (pulse wave velocity), and inflammatory vascular markers. The mechanism is presumed to involve restoration of more youthful endothelial gene expression patterns, supporting nitric oxide synthesis and reducing endothelial inflammation.
Vesugen is sold by research-chemical vendors outside Russia. Western clinical data is essentially absent. The compound should not be used as a substitute for evidence-based cardiovascular therapies (statins, ACE inhibitors, antiplatelet agents) in patients with established cardiovascular disease.
Vesugen was developed in the 2000s as part of the Khavinson bioregulator program, with the KED tripeptide identified as a vascular-targeting active sequence. The compound entered Russian clinical observational use through the 2000s and 2010s, including studies of vascular aging and endothelial dysfunction.
Russian clinical use has reported good tolerability in cardiovascular-risk patient populations. The very short tripeptide structure means systemic side effects are unlikely at typical doses. Western safety validation is essentially absent.
Dose Range
1-5 mg
Frequency
Once daily (SubQ) or sublingual
Duration
10-20 day cycles, repeated 2-3 times per year
Dosing information is for educational purposes only. Consult a healthcare professional before using any peptide.
Typical Vial Size
20 mg
Water Type
Bacteriostatic water (BAC water)
Mixing Volume
2 mL
Half-Life
Short (minutes); biological effect persists via gene-expression modulation
Molecular Weight
391 Da (KED tripeptide)
Store reconstituted vial refrigerated at 2-8°C. Use within 21-30 days. Sublingual or subcutaneous administration is typical.
FDA Status
Not FDA approved.
Legal Status
Unregulated research chemical outside Russia.
USA
Not approvedResearch-only
EU
Not approvedNot authorized as medicinal product
UK
Not approvedClassified as research chemical
Russia
Used in clinical practiceUsed as bioregulator in Russian cardiology and gerontology
Australia
Not approvedTGA has not evaluated
Canada
Not approvedNot authorized for human use
Khavinson VK, Kuznik BI, Tarnovskaya SI, Linkova NS
Bulletin of Experimental Biology and Medicine (2015)
Foundational Khavinson-group review covering vascular-targeting bioregulators including Vesugen.
View Study →Khavinson VK, Anisimov VN, Linkova NS, Bakhmet AA
Bulletin of Experimental Biology and Medicine (2020)
Modern Khavinson-group mechanistic review applicable to vascular bioregulators including Vesugen.
View Study →Khavinson VK, Kuznik BI, Korkushko OV
Advances in Gerontology (2018)
Russian-group review of vascular peptide bioregulators including Vesugen in the context of arterial aging and endothelial dysfunction.
View Study →Khavinson short peptide bioregulator targeting cardiac muscle and vascular endothelium.
Khavinson short peptide bioregulator targeting urinary bladder epithelium.
Mitochondria-targeted tetrapeptide that restores bioenergetics by stabilizing cardiolipin.
Track Vesugen and more with PinnyPeptide.
Sign Up to Track VesugenFree forever · defaults pre-filled from this article